Drug Search Results
More Filters [+]

KPG-818

Alternative Names: kpg-818, kpg 818, kpg818
Latest Update: 2024-06-10
Latest Update Note: News Article

Product Description

KPG-818 significantly inhibits tumor growth in MM.1S multiple myeloma, WSU-DLCL-2 diffuse large B cell lymphoma, DOHH-2 follicular lymphoma, REC-1 mantle cell lymphoma xenograft models. Importantly, KPG-818 prolongs the survival of the mouse cohorts bearing systemic human H929 multiple myeloma in a dose-dependent manner. Moreover, KPG-818 shows favorable DMPK and toxicity profiles in pre-clinical IND enabling studies. (Sourced from: https://aacrjournals.org/cancerres/article/80/16_Supplement/6367/640997/Abstract-6367-KPG-818-a-novel-cereblon-modulator)

Mechanisms of Action: CRBN Modulator,IKZF1 Inducer,IKZF3 Inducer

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Kangpu Biopharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KPG-818

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Lupus Erythematosus, Systemic

Phase 1: Adult T-Cell Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Hodgkin Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Multiple Myeloma|T-Cell Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

KPG-818-HEM-101

P1

Recruiting

Lymphocytic Chronic B-Cell Leukemia|Adult T-Cell Leukemia-Lymphoma|Hodgkin Lymphoma|Multiple Myeloma|T-Cell Lymphoma|Follicular Lymphoma|Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma

2024-10-01

21%

Lupus

P2

Completed

Lupus Erythematosus, Systemic

2023-08-18

49%

Recent News Events